Core Viewpoint - Annexon, Inc. has announced a public offering of common stock and prefunded warrants, aiming to raise approximately $125 million to support its clinical platform for neuroinflammatory diseases [1][2]. Group 1: Offering Details - The public offering consists of 13,001,120 shares priced at $6.25 per share and prefunded warrants for 7,000,000 shares at a price of $6.249 per share [1]. - The total gross proceeds from the offering are expected to be $125 million before deducting underwriting discounts and commissions [2]. - The offering is set to close on June 7, 2024, subject to customary closing conditions, with underwriters granted a 30-day option to purchase an additional 3,000,168 shares [2]. Group 2: Company Overview - Annexon is a biopharmaceutical company focused on developing therapies for classical complement-mediated neuroinflammatory diseases affecting the body, brain, and eye [5]. - The company's approach targets upstream C1q to inhibit the classical complement inflammatory cascade, with ongoing clinical trials for conditions such as Guillain-Barré syndrome and Huntington's disease [5].
Annexon Announces Pricing of $125 Million Underwritten Public Offering